Compare Mesoblast Limited (MESO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Warner Music Group Corp — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Warner Music Group Corp trades at $24.78 (market cap $13.12B). The key difference: Warner Music Group Corp is far larger — about 5.9× Mesoblast Limited's market cap, and Warner Music Group Corp pays a 3.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WMG | |
|---|---|---|
Market Cap | $2.21B | $13.12B |
Sector | Technology | Media |
52-Week High | $20.96 | $34.72 |
52-Week Low | $12.88 | $23.65 |
Enterprise Value | $2.21B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Warner Music Group (WMG) trades at $26.41, up 0.08% on the day, with a bearish technical signal but improving fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $7.3B projected for 2026. The stock shows a P/E of 20.06 and net income margin of 9.2%, supported by strong cash flow and dividend payments. Key resistance is at $27, with support at $26.
WMG presents a mixed outlook: bullish fundamentals with earnings beats and growth, but technicals indicate near-term pressure. Opportunities include streaming expansion and AI integration, while risks involve leadership changes and market volatility. Analyst consensus is 66.7% buy, suggesting long-term value if technical resistance is overcome.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
